Sorafenib treatment of patients with intermediate and advanced hepatocellular carcinoma-institutional experience

Introduction: Hepatocellular carcinoma is the third leading cause of cancer related death globally with gradually growing incidence. In more than 80% of the cases it develops in cirrhotic liver. During the course of the treatment we have to take in account the stage of the underlying liver disease. In 60–70% of the patients hepatocellular carcinoma is diagnosed at intermediate or advanced stage, when the prognosis of the disease is poor because of the lack of effective treating options. Sorafenib is a new drug for the systemic treatment of hepatocellular carcinoma; it inhibits tumor cell proliferation and angiog…